• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Teligent Receives Fourth FDA Approval on 2017

    Bryan Mc Govern
    Aug. 22, 2017 09:43AM PST
    Pharmaceutical Investing

    Teligent received approval from the US Food and Drug Administration for Clobetasol Propionate Cream USP, 0.05%, Emollient.

    Teligent (NASDAQ:TLGT) received approval from the US Food and Drug Administration for Clobetasol Propionate Cream USP, 0.05 percent, Emollient.
    As quoted in the press release:

    This is Teligent’s fourth approval for 2017, and its fifteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

    Based on recent QuintilesIMS Health data from June 2017, the total addressable market for this product is approximately $12.0 million.

    “Clobetasol Propionate Cream USP, 0.05%, Emollient is Teligent’s fourth FDA approval in 2017,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “Teligent now has twenty topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products. We expect to launch this product in the fourth quarter of 2017.”

    Click here to read the full press release.

    Source: globenewswire.com

    pharmaceutical investingfda approvalus food and drug administrationpharmaceutical productsfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES